Pearce IP BioBlast™: w/e 03 Apr 2020

by , | Apr 6, 2020

Significant biosimilar activities this week include

30 Mar 20 | Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab) and Herticad® (trastuzumab), with a launch expected in 2020.

30 Mar 20 | In response to CoVid-19, Genentech announced it would extend physician payment terms for Lucentis® (ranibizumab) purchases to 120 days, up from the previous 60 day term. These new terms will be implemented from 01 April, 2020, as well as retroactively for Lucentis® purchased on or after March 1, 2020.

01 Apr 20 | A new study reported that Truxima® (rituximab) is comparable to the originator in terms of efficacy and safety in the treatment of multiple sclerosis. Rituximab is not currently indicated for multiple sclerosis but it is used off-label in some cases and is under investigation as a potential treatment.

02 Apr 20 | Pfizer announced EC approval of Ruxience® (rituximab) for the treatment of non-hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News